Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Dengue: early-phase trial registry

A small indexed set (10 trials) with no open enrollment listed right now.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count

Dengue: 10 US clinical trials tracked, none currently recruiting.

Dengue is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 6 of these trials.

Enrollment posture brief

Registry condition dengue

OPEN 0 | RECR 0% | LATE 0 | EARLY 8 | RANK #1724 | SPON 6

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Dengue (this)0%
Open-enrollment share among volume-matched conditions near Dengue

Dengue has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dengue on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dengue is recruiting below its size-band peers.

    0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Dengue research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 6 of 10 trials (60%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Dengue trials plan to enrol fewer than 100 people.

    Median target enrolment is 72 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. Dengue research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 21

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED 35,035 participants

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross

Gen-Probe, Incorporated

NCT01656174

COMPLETED Phase 2 390 participants

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Sanofi Pasteur, a Sanofi Company

NCT01488890

COMPLETED NA 95 participants

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03641339

COMPLETED Phase 1 80 participants

TDENV PIV and LAV Dengue Prime-boost Strategy

U.S. Army Medical Research and Development Command

NCT02239614

COMPLETED Phase 1 72 participants

Tetravalent Chimeric Dengue Vaccine Trial

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01110551

COMPLETED Phase 1 58 participants

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01506570

COMPLETED Phase 1 48 participants

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02317900

COMPLETED Phase 1 29 participants

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00712803

COMPLETED Phase 1 12 participants

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02392325

COMPLETED Phase 1 10 participants

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

University of Maryland, Baltimore

NCT04786457

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1

Named interventions

Most-linked intervention names on Dengue records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Biological
3 trials
Modified Live Tetravalent Chimeric Dengue Vaccine (ID) Biological
1 trials
Modified Live Tetravalent Chimeric Dengue Vaccine (SC) Biological
1 trials
Placebo (ID) Drug
1 trials
Yellow Fever Biological
1 trials
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus Biological
1 trials
Procleix Dengue Virus Assay Device
1 trials
rDEN2Δ30-7169 Biological
1 trials

US sites by state

Facility locations filed on Dengue trials. A trial with sites in several states counts in each.

Maryland 8 trials
Vermont 2 trials
Missouri 2 trials
Utah 1 trials
Nevada 1 trials
North Carolina 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dengue page

10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dengue condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.